Diferencia entre revisiones de «Malaria»
Sin resumen de edición |
Sin resumen de edición |
||
| Línea 22: | Línea 22: | ||
'''Severe''' | '''Severe''' | ||
*Any one of the following: | *Any one of the following: | ||
**AMS/coma | **[[AMS]]/coma | ||
**Severe normocytic anemia [hemoglobin < 7] | **Severe normocytic anemia [hemoglobin < 7] | ||
**Renal failure | **Renal failure | ||
**ARDS | **[[ARDS]] | ||
**Hypotension | **[[Hypotension]] | ||
**DIC | **[[DIC]] | ||
**Spontaneous bleeding | **Spontaneous bleeding | ||
**Acidosis | **Acidosis | ||
**Hemoglobinuria | **Hemoglobinuria | ||
**Jaundice | **[[Jaundice]] | ||
**Repeated generalized seizures | **Repeated generalized [[seizures]] | ||
**Parasitemia >5% | **Parasitemia >5% | ||
| Línea 41: | Línea 41: | ||
{{Fever in Traveler DDX}} | {{Fever in Traveler DDX}} | ||
== | ==Diagnosis== | ||
*First smear positive in >90% of cases (thick and thin Giemsa stain) | *First smear positive in >90% of cases (thick and thin Giemsa stain) | ||
**If initial negative, must be repeated BID x 2-3 days for proper exclusion of malaria | **If initial negative, must be repeated BID x 2-3 days for proper exclusion of malaria | ||
| Línea 69: | Línea 69: | ||
===Uncomplicated Malaria=== | ===Uncomplicated Malaria=== | ||
*Chloroquine-sensitive areas: Central America, Caribbean | *Chloroquine-sensitive areas: Central America, Caribbean | ||
*Chloroquine-resistant areas: S. America, S. Asia, | *Chloroquine-resistant areas: S. America, S. Asia, Africa | ||
*[[Atovaquone-proguanil]] '''OR''' | *[[Atovaquone-proguanil]] '''OR''' | ||
*Arthemeter-lumefantrine '''OR''' | *Arthemeter-lumefantrine '''OR''' | ||
| Línea 92: | Línea 92: | ||
**Cerebral malaria (e.g. [[AMS]], repeated [[seizures]], coma) | **Cerebral malaria (e.g. [[AMS]], repeated [[seizures]], coma) | ||
**Parasitemia | **Parasitemia | ||
***>2% in | ***>2% in non-immune (i.e. travelers) | ||
***>5% in | ***>5% in semi-immune (i.e. locals) | ||
==See Also== | ==See Also== | ||
Revisión del 06:26 14 dic 2015
Background
- Caused by parasitic protozoa species of the genus Plasmodium (P ovale, P vivax, P malariae, P knowlesi, and P falciparum) carried by the Anopheles mosquito
- P falciparum most severe
- Failure to consider for febrile illness following travel, even if seemingly temporally remote, can result in significant morbidity or mortality, especially in children and pregnant or immunocompromised patients
- Chemoprophylaxsis does not guarantee protection
- CDC Malaria Hotline: 770-488-7788
- Malaria is a US nationally notifiable disease and all cases should be reported
Traveler Precautions
The CDC recommends travelers to malaria-endemic regions take the following precautions:[1]
- Chemoprophylaxis
- Use of insecticide-treated bed nets
- Use of DEET-containing insect repellents
- Wear long-sleeve shirts and pants
Clinical Features
- Fever + exposure to endemic country
- Cyclic fever only after chronic infection
- Headache, cough, GI symptoms
Classification
Severe
- Any one of the following:
Uncomplicated
- None of the above
Differential Diagnosis
Fever in traveler
- Normal causes of acute fever!
- Malaria
- Dengue
- Leptospirosis
- Typhoid fever
- Typhus
- Viral hemorrhagic fevers
- Chikungunya
- Yellow fever
- Rift valley fever
- Q fever
- Amebiasis
- Zika virus
Diagnosis
- First smear positive in >90% of cases (thick and thin Giemsa stain)
- If initial negative, must be repeated BID x 2-3 days for proper exclusion of malaria
- Determines degree of parasitemia and type (i.e. P. falciparum)
- Additional lab findings
- Normocytic anemia
- Thrombocytopenia
- ↑ ESR
- ↑ LDH
- LFT abnormalities
- ↑ Cr
- Hyponatremia
- Hypoglycemia
- False positive VDRL
Management[2]
- Mixed infections involving more than one species of Plasmodium may occur in areas of high endemicity (have a low threshold for including treatment for P falciparum)
- Hyponatremia in the setting of hypovolemia does not require treatment beyond rehydration
- Treat hypoglycemia
- Check HIV status (coinfection can lead to worse clinical outcomes)
- Exchange transfusion for patients with:
- P falciparum malaria with a parasitemia greater than 10%
- Life-threatening complications (ie, coma, respiratory failure, coagulopathy, fulminant kidney failure)
- For specific dosing see the CDC Recommendations or call the Malaria CDC Hotline(855) 856-4713
Uncomplicated Malaria
- Chloroquine-sensitive areas: Central America, Caribbean
- Chloroquine-resistant areas: S. America, S. Asia, Africa
- Atovaquone-proguanil OR
- Arthemeter-lumefantrine OR
- Quinine plus Tetracycline, doxycycline, or clindamycin
Severe Malaria
- Intravenous quinidine plus tetracycline, or doxycycline or clindamycin
Cerebral Malaria
- Insufficient evidence for or against giving antiepileptics
- For severe cerebral edema, mannitol and steroids have not shown a demonstrable benefit
Disposition
- Admit for:
- Patients with suspected or confirmed P falciparum or P knowlesi infection
- Young children
- Pregnant women
- Immunocompromised patients
- Admit to ICU for:
See Also
References
- ↑ WHO Malaria Policy Advisory Committee and Secretariat. Malaria Policy Advisory Committee to the WHO: conlusionsions and recommendations of September 2013 meeting. Malar J. 2013;12(1):456
- ↑ World Health Organization. Guidelines for the treatment of malaria. Second edition. Geneva: World Health Organization; 2009:1-194
